6 weeks after IPO
Saturday, July 13, 2013
Alcobra (ADHD) began trading on the NASDAQ on 22 May 2013
Alcobra Ltd. (ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, visited the NASDAQ MarketSite in Times Square to celebrate its recent initial public offering (IPO), which occurred on May 22, 2013.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment